期刊文献+

miR-124通过靶向调控PKM2基因的表达抑制前列腺癌PC3细胞的增殖 被引量:3

miR-124 suppresses the proliferation of human prostate cancer PC3 cells by targeting PKM2
下载PDF
导出
摘要 目的:探讨miR-124抑制前列腺癌PC3细胞增殖活性的机制。方法:利用荧光素酶报告基因验证miR-124能否靶向作用于丙酮酸激酶M2型(PKM2)3'端非编码区(UTR)。将miR-124 mimic转染至PC3细胞后,采用实时荧光定量PCR和Western印迹检测前列腺癌PC3细胞PKM2 mRNA和蛋白的表达水平,MTT法检测miR-124 mimic与PKM2 siRNA对PC3细胞生长活性的影响。结果:与人前列腺上皮细胞RWPE-1比较,PC3细胞中PKM2 mRNA和蛋白水平表达分别上调(5.12±0.35)倍和(4.05±0.20)倍(P<0.05)。荧光素酶报告基因结果证实,PKM2是miR-124调控的靶基因,miR-124可特异性地结合于PKM2 mRNA的3'-UTR。转染miR-124 mimic 24 h后,PKM2蛋白水平下调至阴性对照组(0.16±0.04)倍(P<0.05),但对PKM2 mRNA表达无显著影响(P>0.05)。MTT结果显示,转染miR-124 mimic和PKM2 siRNA都能显著抑制PC3细胞的增殖,但miR-124 mimic对PC3细胞生长活性的抑制能力较PKM2 siRNA强。转染miR-124 mimic和PKM2 siRNA 24 h和48 h后,PC3细胞的增殖率分别为(66.20±5.10)%和(82.10±6.35)%(P<0.05)、(49.34±2.37)%和(70.10±5.80)%(P<0.05)。结论:miR-124可通过靶向调控PKM2基因的表达而抑制前列腺癌PC3细胞的增殖。 Objective : To explore the mechanism of miR-124 inhibiting the proliferative activity of prostate cancer PC3 cells. Methods: Luciferase reporter gene assay was used to examine the specific binding ability of miR-124 to PKM2 mRNA 3-UTR. After miR-124 was transfected mimic to PC3 cells, the expression levels of PKM2 mRNA and protein were detected by real-time fluorescence quantitative PCR (qRT-PCR) and Western blot, respectively. The effects of miR-124 mimic and PKM2 siRNA on the proliferative activity of the PC3 cells were determined by MTT assay. Results : The expressions of PKM2 mRNA and protein were upregulated (5.12 ±0.35) times and (4.05 ±0.20) times respectively in the PC3 cells as compared with those in the RWPE-1 cells (P 〈0.05). Luciferase reporter gene assay demonstrated that miR-124 targeted PKM2 3-UTR. At 24 hours after transfection with miR-124 mimic, the PKM2 protein expression in the PC3 cells was downregulated (0.16 ±0.04) times (P 〈0.05), while the PKM2 mRNA level was not changed significantly (P 〉 0.05 ), as compared with the control group. MTT assay showed that both miRNA-124 mimic and PKM2 siRNA could inhibit the proliferation of the PC3 cells, but the former exhibited a greater inhibitory effect than the latter. After transfection with miR-124 mimic and PKM2 siRNA, the cell growth rates were (66.20 ±5.10)% vs (82.10 ±6.35)% at 24 hours (P 〈 0.05) and (49.34 ±2.37)% vs (70.10±5.80)% at48 hours (P〈0.05). Conclusion: miR-124 can suppress the proliferation of PC3 cells by regulating the PKM2 gene.
出处 《中华男科学杂志》 CAS CSCD 2014年第6期495-499,共5页 National Journal of Andrology
基金 国家自然科学基金(30972980 81172423 81001132)~~
关键词 miR-124 丙酮酸激酶M2型 前列腺癌 PC3细胞 细胞增殖 miR-124 pyruvate kinase M2 prostate cancer PC3 cell cell proliferation
  • 相关文献

参考文献16

  • 1朱刚,刘明,万奔.早期前列腺癌的诊断与治疗[J].中华男科学杂志,2005,11(9):693-696. 被引量:31
  • 2谢黎明,贺荣芳,张志伟,唐云云,罗招阳.miR-124抑制胃癌细胞增殖和侵袭的机制研究[J].中华肿瘤杂志,2013,35(7):497-500. 被引量:2
  • 3Han ZB, Yang Z, Chi Y, et al. MicroRNA-124 suppresses breast cancer cell growth and motility by targeting CD151. Cell Physiol Biochem, 2013, 31(6): 823-832.
  • 4吕磊,汪良,蒋国松,章传华,曾甫清.沉默PKM2增强藤黄酸诱导人前列腺癌PC3细胞凋亡的敏感性[J].中华男科学杂志,2013,19(2):102-106. 被引量:5
  • 5Christofk HR, Vander Heinden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabo- lism and tumour growth. Nature, 2008, 452(7184) : 230-233.
  • 6Wang LY, Liu YP, Chen YL, et al. Pyruvate kinase M2 plays a dual role on regulation of the EGF/EGFR signaling via E-cadher- in-dependent manner in gastric cancer cells. PLoS One, 2013, 8 (6) : e67542.
  • 7Guo W, Zhang Y, Chen T, et al. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol, 2011, 137( 1 ) : 65-72.
  • 8Hjerpe E, Eqghai Brage S, Carlson J, et al. Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous o- varian cancer. BMC Clin Pathol, 2013, 13 (1) : 30.
  • 9Yang W, Xia Y, Ji H, et al. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature, 2011, 480 (7357) : 118-122.
  • 10Kwon OH, Kang TW, Kim JH, et al. Pyruvate kinase M2 pro- motes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level. Biochem Biophys Res Com- mun, 2012, 423(1) : 38..44.

二级参考文献45

  • 1朱刚,刘明,万奔.早期前列腺癌的诊断与治疗[J].中华男科学杂志,2005,11(9):693-696. 被引量:31
  • 2Kaplan ID, Cox RS, Bagshaw MA. Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup[J]. J Urol, 1993, 149(3):519-522.
  • 3Oefelein MG, Smith N, Carter M, et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies[J]. J Urol, 1995, 154(6):2128-2131.
  • 4Schild SE, Wong WW, Novicki DE, et al. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay[J]. Urology, 1996, 47(6):878-881.
  • 5Crook JM, Bahadur YA, Bociek RG, et al. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen[J]. Cancer, 1997, 79(2):328-336.
  • 6American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy[J]. Int J Radiat Oncol Biol Phys, 1997,37(3):1035-1041.
  • 7Cooperberg MR, Broering JM, Litwin MS, et al. CaPSURE Investigators. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry[J]. J Urol, 2004, 171(4):1393-1401.
  • 8American cancer society. Cancer facts and figures 2003[M]. Atlanta, GA: American Cancer Society.2001.48-51.
  • 9Parkin DM, Muir CS, Whelan SL. Cancer incidence in five continents [M]. Vol 6. IARC Scientific Pub. No 120. Lyon, France: International Agency of Research on Cancer. 1992.76-79.
  • 10Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002[J]. CA Cancer J Clin, 2002, 52(1):23-47.

共引文献35

同被引文献24

  • 1BLACK A R, BLACK J D,AZIZKHAN-CLIFFORD J. Spl and krtippel-like factor family of transcription factors in cell growth regulation and cancer [ J ]. J Cell Physiol, 2001,188 ( 2 ) : 143-160.
  • 2MAZUREK S, BOSCHEK C B, HUGO F, et al. Pyuvate kinase type M2 and its role in tumor growth and spreading[ J]. Semin Cancer Biol, 2005,15 (4) : 300- 308.
  • 3WU X, ZHOU Y, ZHANG K, et al. Isoform-specific interactionof pyruvate kinase with hepatitis C virus NS5B [ J]. FEBS Lett,2008,582( 15 ) :2155-2160.
  • 4LEE J, KIM H K, HAN Y M, et al. Pyruvate kinase isozyme type M2(PKM2) interacts and cooperates with Oct-4 in regu- lating transcription [ J ]. Int J Biochem Cell Bid, 2008,40 ( 5 ) : 1043-1054.
  • 5DISCHER D J, BISHOPRIC N H, WU X, et al. Hypoxia regu- lates beta-enolase and pyruvate kinase-M promoters by modu- lating Spl/Sp3 binding to a conserved GC element[ J]. J Biol Chem, 1998,273 ( 40 ) : 26087- 26093.
  • 6FELDMAN B J, FELDMAN D. The development of androgen independent prostate cancer[ J ]. Nat Rev Cancer ,2001,1 (1) : 34-45.
  • 7LI Y,VONGSANGNAK W,CHEN L,et al. Integrative analysis re- veals disease-associated genes and biomarkers for prostate cancer progression [ J ]. BMC Med Genomics, 2014,7 ( Suppl 1 ) : $3.
  • 8JIANG J, JIA P, ZHAO Z, et al. Key regulators in prostate cancer identified by co-expression module analysis [ J ]. BMC Genomics,2014,15 : 1015.
  • 9BEAVER L M, BUCHANAN A, SOKOLOWSKI E I, et al. Transcriptome analysis reveals a dynamic and differential tran- scriptional response to sulforaphane in normal andprostate cancer cells and suggests a role for Spl in chemoprevention [J]. Mol Nutr Food Res,2014,58(10) :2001-2013.
  • 10CUI Y, NADIMINTY N, LIU C, et al. Upregulation of glucose metabolism by NF-KB2/p52 mediates enzalutamide resist- ance in castration-resistantprostate cancer cells [ J ]. Endocr Relat Cancer, 2014,21 (3) :435-442.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部